REIT and InvIT issuances are attracting significant investor interest, outperforming traditional IPOs amid equity market volatility. These trusts offer stable, annuity-like income from operational assets, providing predictable cash flows and attractive returns, making them a preferred choice for investors seeking resilience and steady income.
Dr Reddy’s Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced
Dr Reddy’s Laboratories Q4 Results: Dr. Reddy’s Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter versus Rs 1,587 crore
May 12, 2026